Bio-Rad Laboratories, Inc. (BIO) Shares Sold by Verition Fund Management LLC

Verition Fund Management LLC reduced its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 12.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,936 shares of the medical research company’s stock after selling 264 shares during the quarter. Verition Fund Management LLC’s holdings in Bio-Rad Laboratories were worth $438,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its holdings in Bio-Rad Laboratories by 1.6% in the second quarter. Ameritas Investment Partners Inc. now owns 6,229 shares of the medical research company’s stock valued at $1,410,000 after buying an additional 100 shares during the last quarter. Martin & Co. Inc. TN increased its holdings in Bio-Rad Laboratories by 0.6% in the second quarter. Martin & Co. Inc. TN now owns 6,825 shares of the medical research company’s stock valued at $1,545,000 after buying an additional 40 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in Bio-Rad Laboratories by 1.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,364 shares of the medical research company’s stock valued at $1,440,000 after buying an additional 78 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Bio-Rad Laboratories by 20.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 13,000 shares of the medical research company’s stock valued at $2,942,000 after buying an additional 2,200 shares during the last quarter. Finally, Caxton Associates LP bought a new stake in Bio-Rad Laboratories in the second quarter valued at about $657,000. 62.84% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://transcriptdaily.com/2017/10/20/bio-rad-laboratories-inc-bio-shares-sold-by-verition-fund-management-llc.html.

Bio-Rad Laboratories, Inc. (BIO) opened at 219.04 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $154.89 and a 12-month high of $242.79. The company has a market capitalization of $6.49 billion, a price-to-earnings ratio of 432.89 and a beta of 0.91. The stock’s 50 day moving average price is $222.91 and its 200 day moving average price is $221.60.

Several analysts recently weighed in on the company. Zacks Investment Research lowered Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 target price on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Deutsche Bank AG reaffirmed a “buy” rating and set a $255.00 target price on shares of Bio-Rad Laboratories in a report on Monday, September 18th. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Finally, Wells Fargo & Co initiated coverage on Bio-Rad Laboratories in a report on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $260.00.

In other news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares in the company, valued at approximately $444,774.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.29% of the stock is owned by insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply